Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3872 participants.

Also called NCT02876835

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,872 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02876835
  • EudraCT 2016-000542-65
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Colombia, Czechia, Denmark, Estonia, France, Germany, Greece, Hong Kong SAR China, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Portugal, Romania, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02876835. Randomized; no masking; primary purpose treatment. Start 2016-09-27 (actual); primary completion 2021-04-19 (actual). Results posted on 2022-04-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Condition
Anaemia
Intervention (Drug)
Daprodustat
Intervention (Drug)
Darbepoetin alfa
Intervention (Drug)
Placebo
Intervention (Drug)
Iron Therapy
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct02876835
Content hash
9b00828b6dd9570b69ba5b42fee6d3f86892f618666bdc6ddcbaacda73dc87f7